Table 1.

QLQ-CIPN20, PRO-CTCAE™, and TNSc© Sample statistics at each study visit

Measure	Mean (SD)	Median (range)	Proportion at floor (%)	Proportion at ceiling (%)
PRO-CTCAE numbness and tingling severity
T1 (n = 140)	0.79 (0.78)	1 (0–3)	57 (40.7%)	0
T2 (n = 137)	0.91 (0.84)	1 (0–3)	50 (36.5%)	0
T3 (n = 138)	1.08 (0.88)	1 (0–4)	40 (29%)	1 (0.07%)
T4 (n = 123)	1.03 (0.83)	1 (0–3)	35 (28.5%)	0
PRO-CTCAE numbness and tingling interference
T1 (n = 139)	0.25 (0.54)	0 (0–2)	111 (79.9%)	0
T2 (n = 140)	0.49 (0.79)	0 (0–3)	93 (66.4%)	0
T3 (n = 138)	0.55 (0.76)	0 (0–3)	83 (60.1%)	0
T4 (n = 126)	0.52 (0.72)	0 (0–3)	76 (60.3%)	0
QLQ-CIPN20 sensory
T1 (n = 140)	7.84 (10.51)	3.70 (0–55.56	56 (40%)	0
T2 (n = 140)	11.02 (11.02)	7.41 (0–55.56)	33 (23.6%)	0
T3 (n = 138)	11.92 (11.88)	7.41 (0–55.56)	33 (23.9%)	0
QLQ-CIPN20 motor
T1 (n = 140)	5.15 (7.60)	0 (0–37.5)	75 (53.6%)	0
T2 (n = 139)	7.61 (9.74)	4.17 (0–50)	58 (41.7%)	0
T3 (n = 138)	8.49 (10.57)	4.17 (0–54.17)	54 (39.1%)	0
0–10 NRS of worst CIPN pain Intensity
T1 (n = 138)	1.41 (1.98)	0 (0–9)	71 (51.4%)	0
T2 (n = 139)	1.99 (2.41)	1 (0–10)	61 (43.9%)	0
T3 (n = 138)	1.97 (2.16)	1 (0–9)	58 (42%)	0
TNSc©
T3 (n = 118)	6.75 (2.9)	7 (1–13)	0	0

Table describes sample statistics for PRO-CTCAE item (Range = 0–4) QLQ-CIPN20 sensory and motor subscale (Range = 0–100), 0–10 NRS of worst CIPN pain intensity (Range = 0–10) and TNSc© (Range = 0–20) scores at each study time point (T1–T4). Higher scores on all measures represent worse CIPN severity

CIPN-Chemotherapy-Induced Peripheral Neuropathy, PRO-CTCAE™—Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events, QLQ-CIPN20-Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy Scale, TNSc©—Total Neuropathy Score-Clinical Version